Site News

Added 1 day ago Drug news

Phase III trial of Imbruvica + chemo fails to meet endpoint in pancreatic cancer.- AbbVie

AbbVie announced an update on the Phase III RESOLVE trial (PCYC-1137) of Imbruvica (ibrutinib) in combination with chemotherapy agents nab-paclitaxel...

Added 1 day ago Drug news

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

Added 1 day ago Drug news

FDA Advisory Committee recommends Evenity to treat osteoporosis- Amgen + UCB

Amgen and UCB announced strong support from the FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval...

Added 1 day ago Drug news

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

Added 2 days ago Drug news

NICE recommends Venclyxto plus Rituxan in chronic lymphocytic leukaemia.- AbbVie + Genentech/Roche

The National Institute for Health and Care Excellence (NICE) has recommended Venclyxto (venetoclax) with Rituxan (rituximab), from AbbVie + Genentech/Roche,...

Added 2 days ago Drug news

Complete Response Letter for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer . Immunomedics

Immunomedics, Inc. announced it has received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA)...

Added 2 days ago Drug news

NICE recommends Bravtovi + Mektovi combination in melanoma.- Pierre Fabre + Array Biopharma

The UK National Institute for Health and Care Excellence (NICE) has recommended Bravtovi (encorafenib) plus Mektovi (binimetinib) from Pierre Fabre...

Added 2 days ago Drug news

FDA advisory committee voted 8:8 on the overall benefits of Zynquista to treat type 1 diabetes. Sanofi + Lexicon

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted eight to eight on the question of whether the...

Added 2 days ago Drug news

Three post approval studies of sutureless Perceval Aortic Heart Valve.-LivaNova PLC

LivaNova PLC announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval. The...

Added 2 days ago Drug news

Phase III ANNOUNCE study of Lartruvo fails to meet endpoint in soft tissue sarcoma.- Eli Lilly

Eli Lilly reported that the results of ANNOUNCE, the Phase III study of Lartruvo (olaratumab), in combination with doxorubicin in...

Search all news articles